164 related articles for article (PubMed ID: 9159146)
1. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.
Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A
Proc Natl Acad Sci U S A; 1997 May; 94(11):5756-60. PubMed ID: 9159146
[TBL] [Abstract][Full Text] [Related]
2. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice.
Hardy B; Yampolski I; Kovjazin R; Galli M; Novogrodsky A
Cancer Res; 1994 Nov; 54(22):5793-6. PubMed ID: 7954401
[TBL] [Abstract][Full Text] [Related]
3. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.
Becker JC; Pancook JD; Gillies SD; Furukawa K; Reisfeld RA
J Exp Med; 1996 May; 183(5):2361-6. PubMed ID: 8642346
[TBL] [Abstract][Full Text] [Related]
4. Immune stimulatory and anti-tumor properties of anti-CD3 and BAT monoclonal antibodies: a comparative study.
Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A
Hum Antibodies; 1997; 8(2):95-8. PubMed ID: 9289394
[TBL] [Abstract][Full Text] [Related]
5. Autolymphocyte therapy--I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.
Gold JE; Osband ME
Eur J Cancer; 1994; 30A(12):1871-82. PubMed ID: 7880620
[TBL] [Abstract][Full Text] [Related]
6. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
Lum HD; Buhtoiarov IN; Schmidt BE; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Leukoc Biol; 2006 Jun; 79(6):1181-92. PubMed ID: 16565324
[TBL] [Abstract][Full Text] [Related]
7. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
[TBL] [Abstract][Full Text] [Related]
9. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity.
Seaman WE; Sleisenger M; Eriksson E; Koo GC
J Immunol; 1987 Jun; 138(12):4539-44. PubMed ID: 3584981
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.
Turner JG; Rakhmilevich AL; Burdelya L; Neal Z; Imboden M; Sondel PM; Yu H
J Immunol; 2001 Jan; 166(1):89-94. PubMed ID: 11123280
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell-induced activation of adaptive and innate antitumor immunity.
van den Broeke LT; Daschbach E; Thomas EK; Andringa G; Berzofsky JA
J Immunol; 2003 Dec; 171(11):5842-52. PubMed ID: 14634094
[TBL] [Abstract][Full Text] [Related]
12. Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein.
Reisfeld RA; Gillies SD; Mendelsohn J; Varki NM; Becker JC
Cancer Res; 1996 Apr; 56(8):1707-12. PubMed ID: 8620479
[TBL] [Abstract][Full Text] [Related]
13. Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice.
Lozupone F; Pende D; Burgio VL; Castelli C; Spada M; Venditti M; Luciani F; Lugini L; Federici C; Ramoni C; Rivoltini L; Parmiani G; Belardelli F; Rivera P; Marcenaro S; Moretta L; Fais S
Cancer Res; 2004 Jan; 64(1):378-85. PubMed ID: 14729648
[TBL] [Abstract][Full Text] [Related]
14. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ.
Lala PK; Elkashab M; Kerbel RS; Parhar RS
Int Immunol; 1990; 2(12):1149-58. PubMed ID: 2090199
[TBL] [Abstract][Full Text] [Related]
15. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
16. Autolymphocyte therapy. II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.
Gold JE; Osband ME
Clin Immunol Immunopathol; 1994 Jun; 71(3):325-32. PubMed ID: 7911078
[TBL] [Abstract][Full Text] [Related]
17. CD4+ T lymphocytes as a primary cellular target for BAT mAb stimulation.
Raiter A; Rodionov G; Novogrodsky A; Hardy B
Int Immunol; 2000 Nov; 12(11):1623-8. PubMed ID: 11058582
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
19. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals.
Chiyo M; Shimozato O; Yu L; Kawamura K; Iizasa T; Fujisawa T; Tagawa M
Int J Cancer; 2005 Jun; 115(3):437-42. PubMed ID: 15688376
[TBL] [Abstract][Full Text] [Related]
20. Antitumor response independent of functional B or T lymphocytes induced by the local and sustained release of interleukin-2 by the tumor cells.
Alosco T; Croy BA; Gansbacher B; Wang HQ; Rao U; Bankert R
Cancer Immunol Immunother; 1993 Jun; 36(6):364-72. PubMed ID: 8500109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
